PIMCO Access Income Fund (PAXS) currently yields 13.94% and trades at a 7% discount to its net asset value (NAV). However, the fund faces significant credit risk as CCC credit spreads are at historic highs, indicating stress in the riskiest credit segments. The fund uses 39.57% leverage, which increases both its yield and sensitivity to NAV fluctuations. Technical indicators show a bearish trend, and despite the attractive yield and discount, the risks from credit stress, leverage, falling NAV, and negative price momentum lead to a 'Hold' rating for the fund.
PIMCO Access Income Fund (PAXS) offers a 13.94% yield and trades at a 7% discount to NAV, highlighting its high income potential amid credit stress concerns. For readers following US stocks on Pluang, here is the market snapshot as of Oct 24, 2026 02:51 WIB: out of 150 priced stocks, 43 rose and 106 fell. Notable movers include AT&T Inc. (T) down 7.37% with 41% sell orders, Schlumberger NV (SLB) up 7.25% with 83% sell orders, and Halliburton Company (HAL) up 5.18% with 86% sell orders.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
